Skip to main content

5-phenyl-3,4,6,7,8,9-hexahydrobenzothiopheno[2,3-e][1,4]diazepin-2-one

ADVERTISEMENT
Identification
Molecular formula
C17H16N2OS
CAS number
244812-13-6
IUPAC name
5-phenyl-3,4,6,7,8,9-hexahydrobenzothiopheno[2,3-e][1,4]diazepin-2-one
State
State
The compound is a solid at room temperature, presenting as a crystalline powder which is a common state for many synthesized organic compounds and pharmaceuticals.
Melting point (Celsius)
180.00
Melting point (Kelvin)
453.00
Boiling point (Celsius)
450.00
Boiling point (Kelvin)
723.00
General information
Molecular weight
296.39g/mol
Molar mass
297.4000g/mol
Density
1.2100g/cm3
Appearence

5-phenyl-3,4,6,7,8,9-hexahydrobenzothiopheno[2,3-e][1,4]diazepin-2-one appears as a white to off-white crystalline powder. Its appearance in solid form is typical of many organic compounds used in advanced chemical applications and research.

Comment on solubility

Solubility of 5-phenyl-3,4,6,7,8,9-hexahydrobenzothiopheno[2,3-e][1,4]diazepin-2-one

The solubility of 5-phenyl-3,4,6,7,8,9-hexahydrobenzothiopheno[2,3-e][1,4]diazepin-2-one can be quite complex due to its intricate structure. Generally speaking, the solubility of such organic compounds can be influenced by a variety of factors:

  • Polarity: The presence of polar functional groups often enhances solubility in polar solvents such as water. Conversely, non-polar structures tend to be soluble in non-polar solvents like hexane.
  • Hydrogen Bonding: Compounds capable of forming hydrogen bonds typically dissolve better in protic solvents. For this compound, interactions with solvents can significantly affect solubility.
  • Temperature: Increasing temperature generally increases solubility, allowing more compound to dissolve in a solvent.
  • pH Levels: Certain compounds may vary in solubility depending on the acidity or basicity of their environment.

It is important to note that while experimental data may be limited, *the behavior of such compounds in solution often reveals a propensity for low solubility in aqueous media*. For practical applications, solvents such as dimethyl sulfoxide (DMSO) or ethanol may be utilized to enhance the dissolution process.

In summary, understanding the solubility of 5-phenyl-3,4,6,7,8,9-hexahydrobenzothiopheno[2,3-e][1,4]diazepin-2-one can inform its applications and effectiveness in chemical and pharmaceutical contexts.

Interesting facts

Interesting Facts about 5-phenyl-3,4,6,7,8,9-hexahydrobenzothiopheno[2,3-e][1,4]diazepin-2-one

This compound, a member of the benzodiazepine family, presents a fascinating area of study in medicinal chemistry. Here are some key insights:

  • Structural Complexity: The intricate structure of this compound plays a significant role in its biological activity. The presence of both a benzothiophene and a diazepine framework contributes to unique pharmacological properties.
  • Potential Pharmacological Applications: Compounds of this type are often investigated for their potential as anxiolytics, sedatives, or anticonvulsants due to their ability to interact with GABA receptors in the brain.
  • Research Significance: Ongoing studies explore the activity of this compound against various forms of anxiety and depression, making it a point of interest for developing novel therapeutic agents.
  • Synthesis Challenges: The synthesis of this compound may involve multi-step reactions, highlighting the complexity of organic synthesis in producing pharmaceutical compounds.
  • Future Prospects: As research continues, scientists are optimistic about modifying the structure of this compound to enhance its efficacy and safety profile, leading to improved mental health treatments.

In summary, 5-phenyl-3,4,6,7,8,9-hexahydrobenzothiopheno[2,3-e][1,4]diazepin-2-one stands as an important example of how structural intricacies in chemical compounds can lead to profound implications in medicinal chemistry and therapeutics. The exploration of such compounds not only deepens our understanding of pharmacology but also paves the way for innovative solutions in managing neurological disorders.